Guidelines and policy changes for different alert levels in Gauteng. The time intervals are separated by points of inflection identified in Edholm <i>et al</i>. [10]; these points... by Folashade B. Agusto (3663010)

Adjusted odds ratios of skilled delivery and skilled delivery with MAMA kits with community-level variables added one by one (Continuous remittance exposure). by Chelsea Ducille (21540080)

Adjusted odds ratios of skilled delivery and skilled delivery with MAMA kits with community-level variables added one by one (Binary remittance exposure). by Chelsea Ducille (21540080)

Establishment of cBu-1 BAC16 for the isolation of reactivated cell population. by Tomoki Inagaki (12903779)

Subjects:

The all-ages number of incidences urticaria and age-standardized rate of incidence by age. by Wenxi Xiao (22145724)

Subjects:

The all-ages number of incidences urticaria by year. by Wenxi Xiao (22145724)

Subjects:

The all-ages incidence of urticaria, age-standardized percent prevalence, and all ages DALYs cases of 2021 in China. by Wenxi Xiao (22145724)

Subjects:

A Model for MST1-mediated protection in liver fibrosis caused by <i>Schistosoma japonicum</i> infection. by Jianyang Li (461703)

Subjects:

Relationship between τ_<i>i</i> and σ_<i>i</i>. by Zhezhe Zhang (19704587)

“…Under the same <i>JRC</i>, σ_<i>i</i> increases with the increase of τ₁, and Δσ_n decreases with the increasing τ₁. …”

Relationship between τ_<i>i</i> and σ_<i>i</i>. by Zhezhe Zhang (19704587)

“…Under the same <i>JRC</i>, σ_<i>i</i> increases with the increase of τ₁, and Δσ_n decreases with the increasing τ₁. …”

Downregulation of CD36 impaired phagocytic capacity and is associated with a proinflammatory phenotype of <i>Mst1</i> deficiency macrophages. by Jianyang Li (461703)

Subjects:

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Subjects:

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Subjects:

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline T-cell exhaustion, monocyte activation and platelet activation markers through week 12 and week 24 according to the linear regression model. a. by Tosi M. Mwakyandile (16408705)

Subjects:

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Subjects: